Tag Archives: medcomms

Recently, there have been a number of reports and studies exploring the potential therapeutic applications of currently illicit drugs. Cannabis is breaking down barriers in the treatment of certain types of epilepsy in the UK and a marketing application for an intranasal esketamine spray has been submitted to the EMA for treatment-resistant major depressive disorder.

Currently available antidepressants, such as SSRIs, are used collectively to treat major depressive disorder, anxiety and other mood disorders. They have been shown to lack substantial efficacy in all patient populations and are renowned for having a delayed onset of action (Penn and Tracy, 2012). Working in the area of mental health at CHC, coupled with an interest to find out more, we ventured further into a current avenue of research that looked more and more curious…

We work in the area of mental health for one of our clients, which means we can list off the names of prominent thinkers in the field, the main medical meetings, and the DSM-V diagnostic criteria for depression. But, what can be harder to talk about is when someone in our close-knit team is affected by poor mental health. Read more

In this third blog in our series about Delivering Change we provide a brief overview of what CHC means when we talk about change.

‘Change’ has become a buzzword in our industry but more often than not, this ‘change’ only ever relates to behaviour change – changing the prescribing habits of healthcare professionals or changing people’s engagement in their own health. At CHC, we wanted to take this one step further and be more specific about ‘change’. Read more

Those of you who are familiar with CHC might recognise our core values of Building Collaboration, Inspiring Confidence and Delivering Change. After over a year’s worth of valuable qualitative and quantitative research into the ever-evolving needs of those working in pharmaceutical marketing, medical and communications functions, we are thrilled to be launching our new Delivering ChangeTM planning model.Read more

Patient-Pharma interactions are vital for drug development, but are often seen in a negative light. There will always be sceptics; those who think pharma companies have cynical intentions when approaching patients, and conversely, those who feel some patients advocate for the wrong motives. However, in recent years patient advocacy has become a pivotal aspect of the drug development process, where pharma companies have increasingly sought the unique insight that patients can offer.

So can there be a healthy and mutually beneficial relationship between patients and pharmaceutical companies?Read more